Diclofenac Tablet

COMPOSITION:
Each enteric-coated tablet contains 25 mg or 50 mgor 100mgdiclofenacsodium.
PHARMACOLOGICAL CLASSIFICATION:
Antirheumatics (Anti-inflammatory Agents)andAntipyretic analgesics.
PHARMACOLOGICAL ACTION:
Diclofenac sodium is a non-steroidal compound, a phenylacetic acid derivative, with analgesic, antipyretic and anti-inflammatory effects. Diclofenac sodium inhibits the biosynthesis and release of prostaglandins, which are known to be implicated in the pathogenesis of inflammation, pain and fever. LANSAFENAC Tablets are enteric-coated so that absorption occurs in the gastrointestinal tract to give peak plasma concentrations approximately 2 hours after ingestion. There is at least 99% binding to plasma-proteins and excretion of metabolites is mainly in the urine.
DOSAGE AND DIRECTIONS FOR USE:
Usual Adult Dose:
25 to 50 mg taken three times daily. The tablet must be taken whole during or after meals. Initially this dose may be increased to 150 mg daily and may be reduced to 75 to 100 mg daily in milder cases or for long-term and maintenance therapy. Diclofenac sodium is not recommended for use in children as safety and efficacy have not been established.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
In view of the product’s inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients.
Gastric or intestinal ulceration with associated bleeding has been reported - LANSAFENAC therapy should be discontinued immediately in such cases. Skin rashes and gastro-intestinal disturbances may occur. Headache, dizziness, oedema, nervousness, pruritus, tinnitus, insomnia, blurred vision and other ocular reactions, peripheral oedema, malaise, jaundice, elevated transaminase levels, drowsiness and hypersensitivity reactions (eg. bronchospasm) have occurred. Blood counts and monitoring of hepatic and renal function are advised during prolonged therapy with LANSAFENAC as blood dyscrasias have been reported. LANSAFENAC should be given with care to patients with bleeding disorders, cardiovascular disease, and in those who are receiving coumarin anticoagulants. Patients who are sensitive to aspirin generally should not be given LANSAFENAC.
IDENTIFICATION:
25 mg tablet: round,enteric-coated.
50 mg tablet: round, enteric-coated.
100 mg tablet:round, enteric-coated.
PRESENTATION:
LANSAFENAC 25 mg Tablets arepackaged in box with 10tablets or 100 tablets
LANSAFENAC 50 mg Tablets arepackaged in box with 10tablets or 100 tablets
LANSAFENAC100 mg Tablets arepackaged in box with 10tablets or 100 tablets
STORAGE INSTRUCTIONS:
Store below 25°C. Protect from light and moisture. Keep out of reach of children.

Lansa Pharmaceutical Co.,Ltd. is a set of pharmaceutical preparations and chemical company, as one of the large-scale integrated enterprise in China, focusing on scientific research, production, marketing of finished medicines 

and APIs . 

</>

</>

</>

</>